Sirnaomics announces first patient dosed In phase 2a study of STP705

▴ Sirnaomics announces first patient dosed In phase 2a study of STP705
The product candidate has received multiple IND approvals from both the US FDA and Chinese NMPA

Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, announced dose administration for the first patient in a Phase 2a clinical study of the company's lead drug candidate, STP705, for the treatment of cutaneous basal cell carcinoma.

The open label, dose escalation study is designed to evaluate the efficacy and safety of intralesional injection of STP705 in adult patients with cutaneous basal cell carcinoma confirmed with biopsy samples. The objective is to determine the safe and effective recommended dose of STP705 for the treatment of basal cell carcinoma (BCC), as well as analysis of biomarkers common to BCC formation pathway including TGF-β1 and COX-2. The trial is comprised of three dose escalation cohorts ranging from 30 μg to 90 μg with five patients in each group, and a total of 15 patients will be enrolled in the trial. Participants will receive injections of STP705 once a week for up to six weeks.

The primary endpoint of this trial is to evaluate patients for complete histological clearance of the tumour cells within the treated BCC lesion with secondary endpoints, evaluating subjects for investigational product treatment related adverse events, as well as serious adverse events, and cutaneous skin reactions.

"This marks another significant milestone as we continue to leverage our polypeptide nano-particle technology for siRNA drug delivery to advance our pipeline of oncology therapeutic candidates," said Patrick Lu, PhD., the founder, President and CEO of Sirnaomics. "We look forward to obtaining important clinical readouts in this trial and increasing the probability of success, while continuing to demonstrate our leadership in RNAi therapeutic development for skin cancers."

"This is an important study and milestone for Sirnaomics, the STP705 program, and potentially for patients with BCC, as it could offer an alternative to surgical excision of these lesions," said Michael Molyneaux M.D., Chief Medical Officer. "The company recognizes that there is a high unmet need for non-surgical treatments for various types of nonmelanoma skin cancers that reduce scarring and achieve high rates of histological clearance."

The Company expects to report initial clinical data from the trial in 2021.

Basal cell carcinoma (BCC) is a type of nonmelanoma skin cancer that occurs most often on areas that are exposed to the sun, such as head and neck. The most commonly found clinical feature of BCC is an elevated tumor with a pearly and translucent margin and telangiectasia. The color may vary widely from nearly normal skin color to erythematous to violaceous and may also be pigmented. BCC may also resemble noncancerous skin conditions such as eczema or psoriasis. The majority of these cancers occur on areas of skin that are regularly exposed to sunlight or other ultraviolet radiation. It is believed that development of BCC is linked closely to overexpression of TGF-β1 and COX-2.

Surgery is the currently the most common treatment option for the treatment of nonmelanoma cancer. The various forms of surgical modalities carry significant cutaneous adverse events, risk of scar, infection and bleeding. Surgery can also have a significant recurrence rate. As a result, there is a high unmet need for an FDA approved local injection therapy that is safe and effective.

Sirnaomics' leading product candidate, STP705, is a siRNA (small interfering RNA) therapeutic that takes advantage of a dual-targeted inhibitory property and polypeptide nanoparticle (PNP)-enhanced delivery to directly knock down both TGF-β1 and COX-2 gene expression. The product candidate has received multiple IND approvals from both the US FDA and Chinese NMPA, including treatments of cholangiocarcinoma, nonmelanoma skin cancer and hypertrophic scar. STP705 has also received Orphan Drug Designation for treatment of cholangiocarcinoma and primary sclerosing cholangitis. Preclinical animal models using STP705 have demonstrated a dramatic improvement in T-cell penetration into tumours in the liver with single agent action as well as improvement in the efficacy of an anti-PD-L1 antibody checkpoint inhibitor in an HCC model. This effect may improve other immune checkpoint inhibitor efficacies in addition to those targeting the PD-1/PD-L1 axis.

Tags : #SirnaomicsInc #LatestNewsonSirnaomicsInc18thJan #LatestPharmaNews18thJan #LatestResearchonSkinCancer #LatestUSFDAApproval #LatestChineseNMPAApproval #Psoriasis #Eczema

About the Author

Team Medicircle

Related Stories

Loading Please wait...


Trending Now

Freedom Healthy Cooking Oils distributes Seed Ganesha Idols for an eco-friendly festival September 28, 2023
Sadar Hospital,Ranchi Extends Free Cancer Care through Ayushman Bharat Scheme: A ray of hopeSeptember 28, 2023
Dopamine and Its Impact on Your Brain, Feelings, and EmotionsSeptember 28, 2023
Ayushman Bharat-PMJAY: Transforming Healthcare for Millions in IndiaSeptember 28, 2023
Premature Greying of Hair: preventing in the Indian styleSeptember 28, 2023
Run organised to create awareness for Cerebral PalsySeptember 27, 2023
16 Visually challenged explored Skill Development and Employment opportunities in interactive session at FTCCI September 26, 2023
FUJIFILM India celebrates 125 Digital Mammography Machine Installation milestone at the 3rd edition of 'Together Against Breast Cancer' ConferenceSeptember 26, 2023
AI4Rx, the AI powered medical care platform, announces the launch of MedBeat HealthConnectSeptember 26, 2023
Foetal medicine taking rapid strides to optimise Foetal outcomes!September 26, 2023
NGOs bring access to primary health services between 0-3kms for residents of Slums under Jalpally Municipality in line with the UN SDP and Universal Health Coverage modelSeptember 26, 2023
Oliva Skin & Hair Clinic, launches its 25th Clinic in India and 7th in the city, at Dilsukhnagar!September 26, 2023
Badminton sensation Shashidhar brings honor to Telangana and India by clinching the Silver medal at the BWF World Senior Championship in Korea!September 26, 2023
5 Best Homemade Juices to Drink Every Day for a Healthier YouSeptember 26, 2023
Traditionally, men were seen as more profit-oriented in business, but now women are proving they are equally capable - Rahul Jain, a top Indian business coach.September 25, 2023
4-Year-Old Girl Gets New lease of life at American Oncology Institute (AOI) Hyderabad with Haploidentical Stem Cell Transplantation September 25, 2023
Silver Oaks International Schools to provide succor to the underprivileged through its ‘Silver Oaks Street Store’ initiative!September 25, 2023
Sri Pullela Gopichand addressing freshers at OMC, emphasised on focussing on goals to achieve success! September 25, 2023
Fall Prevention Experience Centre for the Elderly Inaugurated at LVPEISeptember 25, 2023
Your Retina, Your Responsibility: 5 Tips For Maintaining Eye HealthSeptember 25, 2023